The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study-Reference-Cited by-同舟云学术

The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study

Published:2021-06-26 Issue: Volume: Page:
ISSN:0971-4502
Container-title:Indian Journal of Hematology and Blood Transfusion
language:en
Short-container-title:Indian J Hematol Blood Transfus

Author:

Ak Muzeyyen Aslaner^ORCID,Sahip Birsen,Geduk Ayfer,Ucar Mehmer Ali,Kale Hacer,Hacibekiroglu Tugba,Polat Merve Gokcen,Kalpakci Yasin,Bolaman Ali Zahit,Guvenc Birol,Ertop Sehmus

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

https://link.springer.com/content/pdf/10.1007/s12288-021-01458-1.pdf

Reference37 articles.

1. Park S, Greenberg P, Yucel A, Farmer C, O’Neill F, De Oliveira BC et al (2019) Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review. Br J Haematol 184:134–160. https://doi.org/10.1111/bjh.15707

2. Malcovati L, Hellström-Lindberg E, Bowen D, Adès L, Cermak J, Del Cañizo C et al (2013) Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 122:2943–2964. https://doi.org/10.1182/blood-2013-03-492884

3. Fenaux P, Haase D, Sanz GF, Santini V, Buske C; ESMO Guidelines Working Group (2017) Myelodysplastic syndromes: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii57–iii69. https://doi.org/10.1093/annonc/mdu180

4. National Comprehensive Cancer Network, Myelodysplastic Syndromes Version 2. 2019. https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed 15 Jan 2021

5. Killick SB, Carter C, Culligan D, Dalley C, Das-Gupta E, Drummond M et al (2014) Guidelines for the diagnosis and management of adult myelodysplastic syndromes. Br J Haematol 164:503–525. https://doi.org/10.1111/bjh.12694

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data;Turkish Journal of Hematology;2023-05-30

2. Myelodysplastic syndrome during pregnancy;Zaporozhye Medical Journal;2022-10-22